Natural History and Treatment of Refractory Celiac Disease: Experience with 17 Patients at a Single Center

2010 ◽  
Vol 105 ◽  
pp. S87-S88
Author(s):  
Christopher Hammerle ◽  
Sheila Crowe
2020 ◽  
Vol 52 ◽  
pp. S23
Author(s):  
P. Soru ◽  
F. Ferretti ◽  
M. Vecchi ◽  
L. Roncoroni ◽  
A. Scricciolo ◽  
...  

2009 ◽  
Vol 136 (1) ◽  
pp. 99-107 ◽  
Author(s):  
Alberto Rubio–Tapia ◽  
Darlene G. Kelly ◽  
Brian D. Lahr ◽  
Ahmet Dogan ◽  
Tsung–Teh Wu ◽  
...  

2016 ◽  
Vol 150 (4) ◽  
pp. S685-S686
Author(s):  
Saurabh S. Mukewar ◽  
Ayush Sharma ◽  
Alberto Rubio-Tapia ◽  
Joseph A. Murray

2016 ◽  
Vol 54 (05) ◽  
Author(s):  
W Eigner ◽  
K Bashir ◽  
C Primas ◽  
L Kazemi-Shirazi ◽  
F Wrba ◽  
...  

2016 ◽  
Vol 25 (3) ◽  
pp. 385-388 ◽  
Author(s):  
Yvette H. Van Beurden ◽  
Tom Van Gils ◽  
Nienke A. Van Gils ◽  
Zain Kassam ◽  
Chris J.J. Mulder ◽  
...  

Treatment of refractory celiac disease type II (RCD II) and preventing the development of an enteropathy associated T-cell lymphoma in these patients is still difficult. In this case report, we describe a patient with RCD II who received fecal microbiota transfer as treatment for a recurrent Clostridium difficile infection, and remarkably showed a full recovery of duodenal villi and disappearance of celiac symptoms. This case suggests that altering the gut microbiota may hold promise in improving the clinical and histological consequences of celiac disease and/or RCD II. Abbreviations: CDI: Clostridium difficile infection; EATL : enteropathy associated T-cell lymphoma; FMT: fecal microbiota transfer; IEL: intraepithelial lymphocytes; RCD II: refractory celiac disease type II; TPN: total parenteral nutrition.


Sign in / Sign up

Export Citation Format

Share Document